Skip to main content

Table 1 Baseline characteristics of the unmatched and propensity score matched cohorts

From: Mid-term outcomes of Sapien 3 versus Perimount Magna Ease for treatment of severe aortic stenosis

 

Unmatched cohort

Propensity score matched cohort

Clinical variables

Sapien 3

(N = 689)

Perimount Magna Ease

(N = 1311)

Standardized difference

p-value

Sapien 3

(N = 308)

Perimount Magna Ease

(N = 308)

Standardized difference

p-value

Age, yrs

81.3 ± 6.4

74.0 ± 6.9

1.1

< 0.0001

78.8 ± 6.9

79.0 ± 5.3

−0.03

0.697

Female

365 (53.0)

556 (42.4)

0.21

< 0.0001

160 (51.9)

165 (53.6)

−0.03

0.674

BMI, kg/m2

27.4 ± 4.9

28.0 ± 4.8

−0.12

0.012

28.1 ± 5.2

28.0 ± 5.0

0.02

0.848

Diabetes mellitus

207 (30.0)

353 (26.9)

0.07

0.140

93 (30.2)

87 (28.2)

0.04

0.578

Atrial fibrillation

293 (42.5)

255 (19.5)

0.52

< 0.0001

102 (33.1)

99 (32.1)

0.02

0.782

Extracardiac arteriopathy

117 (17.0)

137 (10.5)

0.19

< 0.0001

49 (15.9)

41 (13.3)

0.07

0.383

Chronic lung disease

149 (21.6)

172 (13.1)

0.23

< 0.0001

65 (21.1)

62 (20.1)

0.02

0.761

Hemoglobin, g/l

125.7 ± 15.2

133.6 ± 15.1

−0.53

< 0.0001

128.7 ± 15.2

127.8 ± 15.3

0.06

0.421

eGFR, ml/m2/min

62.0 ± 18.5

72.6 ± 16.7

−0.60

< 0.0001

65.6 ± 18.1

66.4 ± 16.1

−0.05

0.550

History of stroke

70 (10.2)

70 (5.3)

0.18

0.0001

27 (8.8)

29 (9.4)

−0.02

0.782

Prior pacemaker

65 (9.4)

50 (3.8)

0.23

< 0.0001

20 (6.5)

19 (6.2)

0.01

0.862

Previous cardiac surgery

110 (16.0)

24 (1.8)

0.51

< 0.0001

17 (5.5)

18 (5.8)

−0.01

0.847

Prior PCI

140 (20.3)

130 (9.9)

0.29

< 0.0001

47 (15.3)

40 (13.0)

0.07

0.370

Coronary artery disease

181 (26.3)

563 (42.9)

−0.36

< 0.0001

102 (33.1)

97 (31.5)

0.04

0.665

No. of diseased vessels

0.36 ± 0.7

0.78 ± 1.1

−0.48

< 0.0001

0.47 ± 0.8

0.46 ± 0.8

0.02

0.836

Recent MI

17 (2.5)

72 (5.5)

−0.16

0.0018

9 (2.9)

9 (2.9)

0.00

1.000

NYHA class IV

82 (11.9)

94 (7.2)

0.16

0.0004

31 (10.1)

34 (11.0)

−0.03

0.696

AHF

75 (10.9)

101 (7.7)

0.11

0.017

33 (10.7)

33 (10.7)

0.00

1.000

Urgent procedure

55 (8.0)

148 (11.3)

−0.11

0.020

28 (9.1)

33 (10.7)

−0.05

0.508

Ejection fraction

  

0.26

< 0.0001

  

0.08

0.699

  > 50%

499 (72.4)

1069 (81.5)

  

230 (74.7)

239 (77.6)

  

 31–50%

158 (22.9)

220 (16.8)

  

68 (22.1)

60 (19.5)

  

 21–30%

31 (4.5)

22 (1.7)

  

10 (3.2)

9 (2.9)

  

Sys. pulmonary pressure

  

0.74

< 0.0001

  

0.09

< 0.0001

 31–55 mmHg

245 (35.6)

524 (40.0)

  

131 (42.5)

121 (39.3)

  

  > 55 mmHg

75 (10.9)

92 (7.0)

  

34 (11.0)

39 (12.7)

  

Mitral valve regurgitation

  

0.56

< 0.0001

  

0.06

0.652

 Mild

255 (37.0)

278 (21.2)

  

116 (37.7)

107 (34.7)

  

 Moderate

80 (11.6)

39 (3.0)

  

23 (7.5)

21 (6.8)

  

Concomitant coronary revascularization

29 (4.2)

511 (39.0)

−0.78

< 0.0001

14 (4.5)

84 (27.3)

−0.62

< 0.0001

EuroSCORE II, %

6.5 ± 7.1

3.4 ± 4.2

0.52

< 0.0001

5.0 ± 5.2

4.9 ± 5.9

0.02

0.752

STS-PROM, %

4.3 ± 2.9

2.6 ± 2.1

0.67

< 0.0001

3.5 ± 2.2

3.5 ± 2.8

0.01

0.918

  1. Categorical values are reported as counts and percentages. Continuous variables are reported as mean and standard deviation. AHF acute heart failure (within 60 days before procedure or critical preoperative state), BMI body mass index, eGFR estimated glomerular filtration rate, EuroSCORE European System for Cardiac Operative Risk Evaluation, MI myocardial infarction within 90 days before procedure, NYHA New York Heart Association, PCI percutaneous coronary intervention, STS-PROM Society of Thoracic Surgeons Predicted Risk of Mortality